LACTOLOGY FOUNDATION

Belladonna alkaloids in ATC class A03BA (atropine, hyoscyamine and belladonna total alkaloids) are antimuscarinic gastrointestinal antispasmodics with a narrow therapeutic index and relevant lactation-related risks, mainly via potential reduction of milk production and anticholinergic toxicity in the infant.medpedia.framar+6

Below is a concise toxicology–lactology monograph suitable as web-page content.

ATC Class A03BA Overview

ATC class A03BA comprises belladonna alkaloids, tertiary amines, used as plain antispasmodic drugs for functional gastrointestinal disorders.atcddd.fhi+2
The main representatives are atropine (A03BA01), hyoscyamine (A03BA03) and belladonna total alkaloids (A03BA04), all derived from Atropa belladonna and related plants rich in tropane alkaloids.atccode+3

Active Substances and Pharmacology

Atropine, hyoscyamine and related belladonna alkaloids act as competitive antagonists at muscarinic acetylcholine receptors, reducing gastrointestinal motility and secretions.medicinenet+1
They relax intestinal smooth muscle, slow transit of intestinal contents and decrease gastric acid and other secretions, which underlies their use in irritable bowel syndrome and other functional GI disorders.drugbank+2

Therapeutic Indications

Within A03BA, belladonna alkaloids are used to treat abdominal pain, cramps, bloating and diarrhea associated with irritable bowel syndrome and functional gastroenteritis, and as adjuncts in duodenal ulcer therapy.clevelandclinic+1
They may also be components of combination products with sedatives such as phenobarbital, enhancing symptomatic relief of spasm and pain in functional gastrointestinal disorders.medicinenet+1

Dosing and Administration

The WHO ATC/DDD system assigns oral defined daily doses of 1.5 mg for atropine (A03BA01), 1.2 mg for hyoscyamine (A03BA03) and 1 mg for belladonna total alkaloids (A03BA04), reflecting typical maintenance exposures in adults.atcddd.fhi+1
Clinical practice doses in oral combination products are titrated individually to achieve spasm control with minimal anticholinergic adverse effects, and parenteral atropine is reserved for specific indications outside the A03BA scope.medpedia.framar+2

General Toxicological Profile

Belladonna alkaloids have a narrow margin between therapeutic and toxic doses, and the plant (Atropa belladonna) itself is historically known for severe poisoning, especially via the root and leaves.pubmed.ncbi.nlm.nih+2
Typical acute anticholinergic toxicity includes mydriasis, dry mouth, tachycardia, hyperthermia, hallucinations, tremor and potentially life-threatening CNS and cardiovascular effects, especially in children and small infants.pubmed.ncbi.nlm.nih+2

Atropine: Toxicology in Adults and Children

Atropine toxicity is dose-dependent and more pronounced in vulnerable populations such as children, the elderly and those with underlying cardiovascular disease.drugbank+1
Accidental or intentional overdose, including ingestion of belladonna-containing herbal preparations, can cause severe anticholinergic syndrome with agitation, delirium, arrhythmias and risk of respiratory failure, requiring intensive care and sometimes physostigmine.drugbank+1

Hyoscyamine and Belladonna Total Alkaloids: Toxicology

Hyoscyamine (levo-atropine) has similar antimuscarinic toxicity to atropine, often considered slightly more potent at muscarinic receptors, so inadvertent overdose may produce marked CNS and peripheral anticholinergic effects.pubmed.ncbi.nlm.nih+1
Belladonna total alkaloids preparations combine varying amounts of atropine, hyoscyamine and scopolamine; variability in composition increases the risk of unpredictable toxicity if dosing is not carefully controlled.medicinenet+2

Special Toxicological Concerns in Pregnancy

For belladonna alkaloid combinations (e.g. atropine–hyoscyamine–scopolamine–phenobarbital), safety in pregnancy has not been adequately evaluated, and use should be restricted to clear indications after benefit–risk assessment.clevelandclinic+1
Potential fetal risks relate mainly to maternal anticholinergic and sedative effects (e.g. phenobarbital) rather than proven teratogenicity, but data are limited and non-essential use, especially in the first trimester, is generally discouraged.clevelandclinic+1

Lactation: Pharmacokinetics and Milk Transfer

Atropine and other belladonna alkaloids are excreted into human breast milk in small quantities, with reported transfer in combination products containing phenobarbital.e-lactation+1
Because these drugs are small molecules with high oral bioavailability, significant infant exposure can occur if maternal doses are high or prolonged, especially with chronic oral therapy rather than single or topical dosing.e-lactation+1

Lactation: Effects on Milk Production

Anticholinergic drugs such as atropine can reduce prolactin and oxytocin secretion, theoretically decreasing milk ejection and, with long-term use, overall milk production.sps+1
Long-standing atropine therapy has been specifically noted as potentially affecting milk supply, so repeated systemic use during breastfeeding warrants monitoring of infant weight gain and maternal milk output.sps+1

Lactation Safety Assessment

E-lactation considers isolated doses or topical atropine to be relatively safe for breastfed infants, classifying it as compatible with breastfeeding with very low risk when exposure is short and doses are modest.e-lactation
In contrast, chronic systemic therapy and combination products containing belladonna alkaloids and phenobarbital are associated with a moderate risk due to possible milk suppression and infant sedation or anticholinergic effects, calling for careful evaluation and follow-up.e-lactation+1

Preferred Alternatives During Breastfeeding

The UK Specialist Pharmacy Service recommends non-belladonna gastrointestinal antispasmodics such as hyoscine butylbromide, propantheline or peppermint oil as preferred choices during breastfeeding, because of their more favourable lactation profiles.sps
When a pure belladonna alkaloid is not essential, switching to these alternatives can reduce theoretical risks of reduced lactation and infant anticholinergic toxicity, particularly in neonates and preterm infants.sps

Clinical Recommendations for Breastfeeding Mothers

For short-term, single-dose or topical use of atropine (e.g. ophthalmic or isolated parenteral dose), breastfeeding can usually continue without interruption, with routine observation of the infant.e-lactation+1
If repeated systemic A03BA therapy is required, clinicians should use the lowest effective dose, limit duration, monitor maternal milk production and infant behaviour, and consider timing doses immediately after breastfeeding to minimise peak milk concentrations.medicinenet+2

Risk in Neonates and Vulnerable Infants

Neonates and young infants are particularly sensitive to anticholinergic effects, including possible feeding difficulties, constipation, urinary retention, hyperthermia and CNS symptoms such as irritability or excessive sedation from combined preparations.pubmed.ncbi.nlm.nih+2
In premature infants, or when high maternal doses are necessary, temporary interruption of breastfeeding or selection of safer non-belladonna antispasmodics should be considered.medicinenet+1

Patient Counselling and Monitoring

Breastfeeding mothers receiving belladonna alkaloids should be counselled about possible symptoms of anticholinergic exposure in their infants (poor feeding, constipation, unusual drowsiness, fever, flushing, or behavioural changes) and advised to seek medical attention if they occur.clevelandclinic+1
Healthcare professionals should document the indication, dose, duration and breastfeeding status, and reassess the benefit–risk balance regularly, with a low threshold for switching to alternative therapies if any lactation or infant safety concerns arise.sps+2